F2 Bio

F2 Bio is a biotechnology company focused on developing novel therapeutics for cardiovascular and metabolic diseases. Launched by Third Rock Ventures, the company leverages a proprietary platform that integrates high-throughput proteomics and human genetics to identify and validate new disease-driving targets. F2 Bio aims to address the significant unmet needs in cardiometabolic health by focusing on pathways that have been historically difficult to target. The company's approach combines deep biological insights with advanced drug discovery capabilities to build a robust pipeline of first-in-class medicines. Led by a team of experienced industry veterans and scientific founders, F2 Bio is positioned to advance the next generation of precision medicines for cardiometabolic health.